<DOC>
	<DOC>NCT00503139</DOC>
	<brief_summary>The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives: 1. To examine the safety of long-term use of Enbrel including the occurrence of malignant tumors. 2. To confirm the efficacy of Enbrel in the long-term use.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria Patients with rheumatoid arthritis (RA) who fulfill all of the following 1. Patients who are refractory to the treatment. 2. Patients who have never been treated with Enbrel and in whom its longterm therapy may be instituted. 3. Patients without a history of or concurrent malignant tumors.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>